Astellas receives permanent J-code for avacincaptad pegol intravitreal solution for GA

News
Article

Since its U.S. launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.

Doctor consulting patient at desk Image Credit: AdobeStock/LiudmilaDutko

Image Credit: AdobeStock/LiudmilaDutko

Iveric Bio, an Astellas company, announced the US Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for avacincaptad pegol intravitreal solution (Izervay) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The new J-code, J2782, is effective April 1, 2024, according to the news release.1

Michael Petroutsas, head of US Commercial, pointed out that GA can lead to irreversible vision loss and early treatment can have a significant impact on patients' lives.

“Receiving a permanent J-code in the US supports our efforts to increase timely patient access to IZERVAY, the first and only FDA approved GA treatment to demonstrate a statistically significant reduction in the rate of GA progression in just 12 months across two pivotal trials,” he said in a news release.

J-codes are used by US government and commercial payers, as well as physicians and their office staff, to streamline the billing and reimbursement process for intravitreal injections and certain other treatments.

Since its US launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices. The permanent J-code for avacincaptad pegol intravitreal solution is expected to accelerate patient access in the U.S. and has been published on the CMS website.2

References:
  1. Inc APU. Astellas Receives Permanent J-code for IZERVAYTM (avacincaptad pegol intravitreal solution) for Geographic Atrophy. www.prnewswire.com. Accessed March 26, 2024. https://www.prnewswire.com/news-releases/astellas-receives-permanent-j-code-for-izervay-avacincaptad-pegol-intravitreal-solution-for-geographic-atrophy-302098783.html
  2. ‌https://www.cms.gov/files/document/2023-hcpcs-application-summary-quarter-4-2023-drugs-and-biologicals-posted-01/26/2024-updated-03/04.pdf
Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
© 2025 MJH Life Sciences

All rights reserved.